1
                                                                    EXHIBIT 99.1


[ENCORE LOGO]

FOR:              ENCORE MEDICAL CORPORATION             FOR IMMEDIATE RELEASE
CONTACT:          NICK CINDRICH/CRAIG SMITH
                  (512) 832-9500


      ENCORE(R) MEDICAL CORPORATION ANNOUNCES THE ACQUISITION OF BIODYNAMIC
                               TECHNOLOGIES, INC.

              ORTHOPEDIC TRAUMA PRODUCT LINE SIGNIFICANTLY EXPANDED
    ----------------------------------------------------------------------------

Austin, Texas, April 6, 1999 - Encore Medical Corporation (NASDAQ: ENMC)
announced today that on March 30, 1999 it completed the acquisition of
Biodynamic Technologies, Inc. ("BTI"), a Florida based company that has
developed and was marketing a broad array of orthopedic trauma products. The
acquisition, which was styled as a purchase, involved Encore buying the
outstanding stock of BTI in exchange for cash and promissory notes payable to
the former shareholders of BTI.

Nick Cindrich, Chairman and Chief Executive Officer of Encore, remarked, "Encore
is extremely excited about this acquisition. A 1999 goal was the continued
expansion of the products that our sales force can offer to the orthopedic
surgeon. Biodynamic Technologies, Inc. has a high-quality line of specialty
trauma products that significantly enhances Encore's competitive position. In
particular, Encore now offers a complete line of specialty products for use in
the treatment of upper extremity orthopedic trauma. We believe that this will
allow our sales representatives greater access to more customers, resulting in
greater future sales."

Encore Medical Corporation (www.encoremed.com) designs, manufactures, and
markets orthopedic total joint, trauma, and spinal implants, as well as
osteobiologic products around the world. Over the past five years, sales have
increased at a compounded annual sales growth rate of over 48 percent.

                                       ###

Except for the historical information contained herein, the matters discussed
are forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These statements involve
risks and uncertainties, such as quarterly fluctuations in operating results,
the timely availability of new products, the impacts of competitive products and
pricing, and other risks and uncertainties set forth in the Company's filings
with the Securities and Exchange Commission. These risks and uncertainties could
cause actual results to differ materially from any forward-looking statements
made herein.